Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Multifaceted roles of PDS5B in RAD51-dependent homology-directed DNA repair and replication fork protection.

Nature communications·2026
Same author

Selective elimination of circulating effector CD8 T cells via LTβR blockade separates anti-CD137 efficacy from toxicity.

Science advances·2026
Same author

Structural insight into how RAD51 paralog exchange regulates RAD51 filament formation.

Nature structural & molecular biology·2026
Same author

PRECLINICAL ACTIVITY OF THE B7-H3- TARGETING ANTIBODY-DRUG CONJUGATE (ADC) VOBRAMITAMAB DUOCARMAZINE (VOBRA DUO) IN PEDIATRIC SOLID TUMORS.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Resolution of R-loops and transcription-replication conflicts by SETX-BRCA1-BARD1 complex.

Nature structural & molecular biology·2026
Same author

Targeting LIPA with ERX-41 Induces ER Stress and Inhibits Tumor Progression in Inflammatory Breast Cancer.

Biomolecules·2026

相关实验视频

Updated: Sep 18, 2025

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

920

针对DDR2用于治疗胰腺癌.

Chris Tp Do1, Prabhakar Pitta Venkata2, Jack Y Prochnau3

  • 1The University of Texas Health Science Center at San Antonio, San Antonio, TX, United States.

Molecular cancer therapeutics
|June 26, 2025
PubMed
概括

迪斯科伊丁域受体2 (DDR2) 驱动胰腺癌的生长. 一种新的抑制剂CIDD-8633有效地阻断瘤生长并增强化疗,为胰腺管腺癌提供了一个有前途的新治疗策略.

更多相关视频

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

11.5K
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

19.7K

相关实验视频

Last Updated: Sep 18, 2025

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

920
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

11.5K
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

19.7K

科学领域:

  • 在瘤学瘤学.
  • 分子生物学分子生物学
  • 药物发现 药物发现 药物发现

背景情况:

  • 胰腺管腺癌 (PDAC) 由于其复杂的瘤微环境, presents一个重要的治疗挑战.
  • 对于PDAC的治疗选择有限,需要新的治疗目标和策略.

研究的目的:

  • 确定和描述PDAC的新型治疗点.
  • 在PDAC.的临床前模型中评估新发现的DDR2抑制剂CIDD-8633的疗效.

主要方法:

  • 小分子库的高通量选以识别DDR2抑制剂.
  • 在体外测试评估CIDD-8633与DDR2的相互作用及其下游信号.
  • 在体内研究使用临床前小鼠模型来评估瘤生长抑制.
  • 用gemcitabine进行组合治疗的研究.

主要成果:

  • 迪斯科伊丁域受体2 (DDR2) 在PDAC中高度表达,与患者的生存率差相关.
  • 鉴定出CIDD-8633是一种针对DDR2.2的新型小分子抑制剂.
  • 在体内,CIDD-8633显著抑制了PDAC瘤生长.
  • 结合治疗的CIDD-8633与凝丁显示了协同效果.
  • 在PDAC细胞中,CIDD-8633治疗诱导了前性基因.

结论:

  • DDR2是PDAC生长和生存的关键驱动因素,代表了一个有前途的治疗标.
  • CIDD-8633是一种强大的DDR2抑制剂,在PDAC中具有显著的临床前疗效.
  • CIDD-8633,单独或与凝胺结合,为PDAC治疗提供了一个潜在的新疗法策略.